{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-23-000048","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.959910+00:00","generated_at":"2026-06-15T19:52:13.785460+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO","bullets":["Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.","Enrolled 9 additional patients at 200mg BID for emavusertib; FDA partial clinical hold discussion expected in Q3 2023.","Appointed Jonathan Zung, Ph.D. as Chief Development Officer effective May 1, 2023; previously CDO at Evelo.","Cash and investments $71.8M as of Dec 31, 2022; cash runway expected into 2025.","R&D expenses down to $9.1M from $11.4M; G&A down to $4.8M from $5.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-23-000048","json":"https://secwatch.observer/filing/0001108205-23-000048.json","markdown":"https://secwatch.observer/filing/0001108205-23-000048.md","text":"https://secwatch.observer/filing/0001108205-23-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/0001108205-23-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/cris-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:52:13.785460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b395a082d3d082d5351da5e931a7aa01f7701c78","claim":"CURIS INC reported the first quarter ended March 31, 2023 results: revenue $2.3 million, net income a net loss of $11.6 million, EPS $0.12 per share on both a basic and diluted basis.","evidence_excerpt":"and diluted basis as compared to $16.1 million or $0.18 per share on both a basic and diluted basis, for the same period in 2022. Revenues for the first quarter of 2023 were $2.3 million as compared to $2.1 million for the same period in 2022. Revenues for both periods consist of royalty revenues from Genentech's and Roche's sales of Erivedge®. Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/0001108205-23-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$2.3 million"},{"label":"Net income","value":"a net loss of $11.6 million"},{"label":"EPS","value":"$0.12 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}